loperamide
Trade name: imodium
Approved
Dec 28, 1976
Loperamide is a commonly used over-the-counter (OTC) and prescription medicine that is approved to help control symptoms of diarrhea, including Travelers’ Diarrhea. The maximum approved daily dose for adults is 8 mg per day for OTC use and 16 mg per day for prescription use. It is sold under the OTC brand name Imodium A-D, as store brands, and as generics. In vitro and animal studies show that IMODIUM® (loperamide hydrochloride) acts by slowing intestinal motility and by affecting water and electrolyte movement through the bowel. Loperamide binds to the opiate receptor in the gut wall. Consequently, it inhibits the release of acetylcholine and prostaglandins, thereby reducing propulsive peristalsis, and increasing intestinal transit time. Loperamide increases the tone of the anal sphincter, thereby reducing incontinence and urgency. Loperamide is also indicated for reducing the volume of discharge from ileostomies. In man, Loperamide prolongs the transit time of the intestinal contents. It reduces the daily fecal volume, increases the viscosity and bulk density, and diminishes the loss of fluid and electrolytes. Tolerance to the antidiarrheal effect has not been observed. Loperamide is an opioid receptor agonist and acts on the mu opioid receptors in the myenteric plexus large intestines; it does not affect the central nervous system like other opioids. It works specifically by decreasing the activity of the myenteric plexus which decreases the motility of the circular and longitudinal smooth muscles of the intestinal wall. This increases the amount of time substances stay in the intestine, allowing for more water to be absorbed out of the fecal matter. Loperamide also decreases colonic mass movements and suppresses the gastrocolic reflex. — NCATS
Clinical trial activity
76 trials · 110 clinical orgs · 31 marketing orgs
Earliest trial started Nov 1, 1996 (NCT00003057)
Timeline
1970s
- Dec 28, 1976
Johnson and Johnson — Earliest FDA Approval
- Dec 28, 1976
Johnson and Johnson — NDA Secondary Org
- Dec 28, 1976
Johnson and Johnson — NDA Organization
1990s
- Aug 30, 1991
Teva — Marketing Organization
- Sep 18, 1991
Mylan — Marketing Organization
- Apr 30, 1992
Allied Pharmaceutical Services — Marketing Organization
- Aug 28, 1992
Fosun — Marketing Organization
- Aug 28, 1992
Chartwell Pharmaceuticals — Marketing Organization
- Sep 15, 1992
Alpharma — Marketing Organization
- Dec 10, 1992
Ohm Laboratories, Inc. — Marketing Organization
- Jul 30, 1993
Contract Pharmacal — Marketing Organization
- Nov 30, 1993
Able Laboratories — Marketing Organization
- Nov 17, 1995
Hi Tech Pharmaceuticals — Marketing Organization
- Nov 17, 1995
Saptalis Pharmaceuticals — Marketing Organization
- Nov 17, 1995
Akorn, Inc. — Marketing Organization
- Nov 17, 1995
Sciegen Pharmaceticals — Marketing Organization
- Jan 1, 1996
Earliest Phase 3 Sponsor(trial)
- Aug 28, 1997
Wockhardt — Marketing Organization
- Dec 29, 1997
Duramed Research — Marketing Organization
2000s
- Jan 6, 2000
Perrigo — Marketing Organization
- Jan 1, 2002
Earliest Phase 1 Sponsor(trial)
- Jun 10, 2003
LNK International — Marketing Organization
- Aug 4, 2005
Bionpharma Inc — NDA Secondary Org
- Aug 4, 2005
Bionpharma Inc — Marketing Organization
- Sep 6, 2006
Sun Pharmaceuticals — Marketing Organization
- Jan 1, 2008
Earliest Phase 2 Sponsor(trial)
2010s
- Dec 15, 2015
Aurobindo Pharma — Marketing Organization
2020s
- May 27, 2021
Guardian Drug — Marketing Organization
- Jun 17, 2021
Hetero Labs Ltd — Marketing Organization
- Aug 11, 2021
Strides Pharma Science — Marketing Organization
- Oct 6, 2021
Edenbridge Pharms — Marketing Organization
- Aug 29, 2022
Granules India — Marketing Organization
- Jan 26, 2023
Rubicon Research — Marketing Organization
- Mar 23, 2023
Zydus Discovery DMCC — Marketing Organization
- Jul 5, 2023
Jubilant Innovation Ltd. — Marketing Organization
Indications
Approved for
Studied for
- Alopecia · Phase 2
- Alopecia Areata · Phase 2
- Breast Neoplasms · Phase 2/Phase 3
- Carcinoma, Non-Small-Cell Lung · Phase 3
- Cardiovascular Diseases · Phase 4
- Clostridioides difficile · Phase 4
- Clostridium Infections · Phase 2/Phase 3
- Colitis · Phase 1
- Colitis, Ulcerative · Phase 3
- Colonoscopy · Phase 3
- Colorectal Neoplasms · Phase 3
- Coronary Artery Disease · Phase 4
- Cystitis · Early Phase 1
- Drug Interactions · Phase 1
- Eczema · Phase 2
- Endometrial Neoplasms · Phase 1/Phase 2
- Fecal Incontinence · Phase 4
- Genital Diseases, Female · Phase 2/Phase 3
- Healthy Volunteers · Phase 1
- Heart Diseases · Phase 4
- Hormones · Phase 2
- Ileostomy · Phase 3
- Intestinal Obstruction · Phase 1
- Irritable Bowel Syndrome · Phase 2/Phase 3
- Kidney Diseases · Phase 4
- Kidney Failure, Chronic · Phase 4
- Lung Neoplasms · Phase 1
- Melanoma · Phase 1
- Multiple Sclerosis, Relapsing-Remitting · Phase 4
- Myocardial Ischemia · Phase 4
- Neoplasm Metastasis · Phase 1
- Neoplasms · Phase 2
- Ovarian Neoplasms · Phase 1/Phase 2
- Pain · Early Phase 1
- Rectal Neoplasms · Phase 3
- Short Bowel Syndrome · Phase 3
- Triple Negative Breast Neoplasms · Phase 2
- Uterine Cervical Neoplasms · Phase 1
- Uterine Neoplasms · Phase 1
Mechanism of action
- Mu opioid receptorAGONIST
OPRM agonist
Combination products
imodium multi-symptom relief
with simethicone
Approval history
- approvedDec 28, 1976
Chemistry & pharmacology
SMILES
CN(C)C(=O)C(CCN1CCC(O)(c2ccc(Cl)cc2)CC1)(c1ccccc1)c1ccccc1- Mol. weight
- 477.05 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
- Availability
- Over the Counter
Oral
Yes
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL841 ↗
- WikipediaLoperamide ↗
- NCATS77TI35393C ↗
- ChEMBLCHEMBL2105114 ↗
- ChEMBLCHEMBL1707 ↗
Also known as
- arestal
- arret
- desmethyl-loperamide
- desmethyl-loperamide
- diah-limit
- diaquitte
- diareze
- diarrhoea relief
- diasorb
- diasorb
- diasorb
- diocalm
- diocaps
- dioraleze
- entrocalm
- gppe pack
- imodium
- imodium
- imodium
- imodium
- imodium a-d
- imodium a-d
- imodium a-d ez chews
- imodium a-d ez chews
- imodium advanced
- imodium advanced
- imodium classic
- imodium ibs relief
- imodium instant melts
- imodium instants
- imodium liquicaps
- lodiar
- loperagen
- loperamid
- loperamid
- loperamida
- loperamida
- loperamide
- loperamide
- loperamide
- loperamide
- loperamide
- loperamide
- loperamide
- loperamide
- loperamide
- loperamide
- loperamide
- lopéramide
- lopéramide
- loperamide hcl
- loperamide hcl
- loperamide hcl
- loperamide hydrochloride
- loperamide hydrochloride
- loperamide hydrochloride
- loperamide hydrochloride
- loperamide hydrochloride
- loperamide oxide
- loperamide oxide
- loperamide oxide monohydrate
- loperamide oxide monohydrate
- loperamide oxide monohydrate
- loperamide oxide monohydrate
- loperamidum
- loperamidum
- norimode
- normaloe
- r-18553
- r-18553
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07195656 | N/A | Sep 30, 2025 | FemPulse Corporation |
| NCT06892093 | N/A | Aug 7, 2025 | Jiangnan University, Sun Yat-Sen University |
| NCT06971172 | N/A | Jun 1, 2025 | Cairo University |
| NCT06946979 | N/A | Apr 30, 2025 | Zhejiang Chinese Medical University |
| NCT06883864 | N/A | Apr 1, 2025 | Abbott, Capital Medical University |
| NCT06693934 | N/A | Nov 30, 2024 | Asia Diabetes Foundation, Chinese University of Hong Kong |
| NCT06299514 | N/A | Apr 25, 2024 | University of Western Ontario |
| NCT07016451 | Early Phase 1 (Phase 1) | Apr 2, 2024 | Mahidol University |
| NCT06377826 | N/A | Apr 1, 2024 | Riphah International University |
| NCT06261801 | N/A | Feb 7, 2024 | Hangzhou Third Hospital, Zhejiang University |
| NCT06101368 | N/A | Jan 1, 2024 | Health Education Research Foundation (HERF), University of Hail |
| NCT05520723 | Phase 2 | Jan 11, 2023 | Gilead Sciences, MedSIR, University of Barcelona |
| NCT05677282 | Phase 4 | Oct 28, 2022 | Henry M. Jackson Foundation for the Advancement of Military Medicine, Uniformed Services University of the Health Sciences |
| NCT05252988 | Phase 2 | Aug 31, 2022 | Hospital General Universitario Gregorio Marañon, Pierre Fabre, Puma Biotechnology, Inc., Spanish Breast Cancer Research Group |
| NCT05480566 | N/A | Jun 1, 2022 | Hasselt University |
| NCT05252546 | Phase 1 | Mar 8, 2022 | Hengrui Therapeutics, Inc. |
| NCT04576208 | Phase 2 | Nov 30, 2020 | Takeda |
| NCT04594226 | N/A | Nov 30, 2020 | Lishui Hospital of Traditional Chinese Medicine, Zhejiang University |
| NCT04446299 | Phase 3 | Jul 13, 2020 | Braintree Laboratories, Sebela Pharmaceuticals |
| NCT04446312 | Phase 3 | Jul 13, 2020 | Braintree Laboratories, Sebela Pharmaceuticals |
Organizations
Research & Development (110)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Johnson and Johnson | For profit | 4 | 4 | 3 | 2005 |
| Puma Biotechnology, Inc. | For profit | 4 | 2 | 1 | 2015 |
| University of Texas at Houston | Academic/Hospital | 4 | 3 | 2 | 2002 |
| Columbia University | Academic/Hospital | 3 | 1 | 3 | 2012 |
| Duke University | Academic/Hospital | 3 | 0 | 3 | 2012 |
| Eli Lilly | For profit | 3 | 3 | 2 | 2015 |
| Zhejiang University | Academic/Hospital | 3 | 2 | 1 | 2020 |
| Boehringer Ingelheim | For profit | 2 | 2 | 2 | 2002 |
| Braintree Laboratories | For profit | 2 | 2 | 1 | 2020 |
| Cairo University | Academic/Hospital | 2 | 2 | 1 | 2018 |
| Cedars-Sinai Medical Center | Academic/Hospital | 2 | 1 | 2 | 2012 |
| Department of Veteran Affairs | Government | 2 | 2 | 2 | 2007 |
| Hengrui Therapeutics, Inc. | For profit | 2 | 2 | 1 | 2020 |
| Linkoping University | Academic/Hospital | 2 | 2 | 1 | 2002 |
| McNeil | For profit | 2 | 1 | 2 | 2008 |
| National Cancer Institute (NCI) | Government | 2 | 0 | 2 | 1996 |
| National Heart, Lung, and Blood Institute (NHLBI) | Government | 2 | 0 | 2 | 2012 |
| New York University | Academic/Hospital | 2 | 2 | 2 | 2012 |
| Sebela Pharmaceuticals | For profit | 2 | 0 | 1 | 2020 |
| Stanford University | Academic/Hospital | 2 | 0 | 2 | 2012 |
Marketing (37)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Able Laboratories | For profit | MKTG | Nov 30, 1993 |
| Akorn, Inc. | For profit | MKTG | Nov 17, 1995 |
| Allied Pharmaceutical Services | For profit | MKTG | Apr 30, 1992 |
| Alpharma | For profit | MKTG | Sep 15, 1992 |
| Aurobindo Pharma | For profit | MKTG | Dec 15, 2015 |
| Aurobindo Pharma | For profit | SYN | Dec 15, 2015 |
| Bionpharma Inc | For profit | NDA2 | Aug 4, 2005 |
| Bionpharma Inc | For profit | MKTG | Aug 4, 2005 |
| Chartwell Pharmaceuticals | For profit | MKTG | Aug 28, 1992 |
| Contract Pharmacal | For profit | MKTG | Jul 30, 1993 |
| Duramed Research | For profit | MKTG | Dec 29, 1997 |
| Edenbridge Pharms | For profit | MKTG | Oct 6, 2021 |
| Fosun | For profit | MKTG | Aug 28, 1992 |
| Granules India | For profit | MKTG | Aug 29, 2022 |
| Guardian Drug | For profit | MKTG | May 27, 2021 |
| Hetero Labs Ltd | For profit | MKTG | Jun 17, 2021 |
| Hi Tech Pharmaceuticals | For profit | MKTG | Nov 17, 1995 |
| Johnson and Johnson | For profit | NDA2 | Dec 28, 1976 |
| Johnson and Johnson | For profit | SYN | Jul 31, 1984 |
| Johnson and Johnson | For profit | NDA | Dec 28, 1976 |
| Jubilant Innovation Ltd. | For profit | MKTG | Jul 5, 2023 |
| LNK International | For profit | MKTG | Jun 10, 2003 |
| Mylan | For profit | MKTG | Sep 18, 1991 |
| Ohm Laboratories, Inc. | For profit | MKTG | Dec 10, 1992 |
| Perrigo | For profit | MKTG | Jan 6, 2000 |
| Perrigo | For profit | SYN | Jan 21, 1992 |
| Perrigo | For profit | SYN | May 20, 2011 |
| Roxane Laboratories | For profit | MKTG | — |
| Rubicon Research | For profit | MKTG | Jan 26, 2023 |
| Saptalis Pharmaceuticals | For profit | MKTG | Nov 17, 1995 |
| Sciegen Pharmaceticals | For profit | MKTG | Nov 17, 1995 |
| Strides Pharma Science | For profit | MKTG | Aug 11, 2021 |
| Sun Pharmaceuticals | For profit | MKTG | Sep 6, 2006 |
| Teva | For profit | MKTG | Aug 30, 1991 |
| Watson Pharmaceuticals | For profit | MKTG | — |
| Wockhardt | For profit | MKTG | Aug 28, 1997 |
| Zydus Discovery DMCC | For profit | MKTG | Mar 23, 2023 |